Known so far: no new shares from the prospectus covers read · shelf room about $7.2M · not yet read: warrants, converts, options, ATM.
Shelf room
Room todayabout $7.2M
One third of float$7.2M ($21.6M float, Jun 30, 2025)
Sold off it, 12 monthsnothing
How this is worked out
Shelf room about $7.2M on the S-3 of Jul 10, 2026: the baby-shelf rule (public float under $75M) caps sales at one third of the $21.6M public float stated as of Jun 30, 2025, $7.2M, nothing sold off it in the last 12 months. Sources: S-3 Jul 10, 2026, effective Jul 16, 2026 · public float, as of Jun 30, 2025.
What could become new FibroBiologics (FBLG) shares, from its 10-Q, 10-K, S-3 or 424B filings.
Read so far: the cover share count (6.7M shares, +225% in average shares, 12 months to Jun 30, 2026, adjusted for a reverse split of about 1-for-13 by May 1, 2026). Not read yet: warrants, convertible notes, options and RSUs and an ATM program.Read them on EDGAR: the latest 10-Q · S-3 shelf filings.
Registrations and share actions on EDGAR (63 filings)
Registration statements, prospectuses, effectiveness notices, information statements and share sales, newest first. Showing the newest 15 of 63. Each links to the filing on EDGAR.
S-1/AAmended registration statement; new shares or resale not read yet
S-1/AAmended registration statement; new shares or resale not read yet
S-1/AAmended registration statement; new shares or resale not read yet
S-1/AAmended registration statement; new shares or resale not read yet
S-1Registration statement; new shares or resale not read yet
Shares outstanding
6.7M
Nov 2024 to Jul 2026: from 2.7M to 6.7M. Adjusted for a reverse split of about 1-for-13 by May 1, 2026: each earlier count is divided by the ratio of every split after it.
From the share count on the cover of each 10-Q and 10-K, dated as each cover states.
Follow FibroBiologics
New shelves, offerings, 10-Qs and 10-Ks from FBLG, explained in plain English when they reach EDGAR.
